FDA Asks Clinical Data to Discuss Regulatory Status of Its Tests | GenomeWeb
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has asked Clinical Data to “discuss the nature and appropriate regulatory status” of the company’s diagnostic tests, Clinical Data said today.
 
Specifically, the firm and the FDA will discuss whether “any regulatory requirements apply, [and] the least burdensome ways that the company may fulfill them,” Clinical Data said.
 
The company said it plans to meet with the FDA “in the near future.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.